spironolactone has been researched along with Osteoporosis, Postmenopausal in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary aldosteronism (PA) is the most frequent form of endocrine hypertension." | 5.56 | Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. ( Adolf, C; Bidlingmaier, M; Braun, LT; Fuss, CT; Hahner, S; Handgriff, L; Heinrich, DA; Künzel, H; Reincke, M; Schneider, H; Sturm, L, 2020) |
| " The recent introduction of a novel, long-acting testosterone formulation (testosterone undecanoate) which only requires one intramuscular injection every 3 months, together with the already available hydroalcoholic testosterone gels, appear to be promising alternatives to the previous standard substitution therapy for male hypogonadism." | 4.83 | [The latest developments in endocrinology 2004/2005]. ( Fottner, C; Weber, MM, 2006) |
| "Primary aldosteronism (PA) is the most frequent form of endocrine hypertension." | 1.56 | Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. ( Adolf, C; Bidlingmaier, M; Braun, LT; Fuss, CT; Hahner, S; Handgriff, L; Heinrich, DA; Künzel, H; Reincke, M; Schneider, H; Sturm, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Adolf, C | 1 |
| Braun, LT | 1 |
| Fuss, CT | 1 |
| Hahner, S | 1 |
| Künzel, H | 1 |
| Handgriff, L | 1 |
| Sturm, L | 1 |
| Heinrich, DA | 1 |
| Schneider, H | 1 |
| Bidlingmaier, M | 1 |
| Reincke, M | 1 |
| Laustsen, G | 1 |
| Wimmett, L | 1 |
| Fottner, C | 1 |
| Weber, MM | 1 |
2 reviews available for spironolactone and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
2004 drug approval highlights: FDA update.
Topics: Administration, Cutaneous; Amlodipine; Anti-Bacterial Agents; Antidepressive Agents; Bronchodilator | 2005 |
[The latest developments in endocrinology 2004/2005].
Topics: Adrenal Gland Neoplasms; Adult; Bone Density Conservation Agents; Chronic Kidney Disease-Mineral and | 2006 |
1 other study available for spironolactone and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Remodeling; Female; Humans; Hyperaldosteronism; | 2020 |